Table 4 The improvement of ascites and lower extremity edema (LOCF)
| Â | Placebo (mg) (N = 76) | Tolvaptan | P value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|  | 7.5 mg/day (N = 153) | 15 mg/day (N = 301) |  | ||||||||||
Improvement | No changes | Degradation | Improvement | No changes | Degradation | Improvement | No changes | Degradation | 7.5Â mg Tolvaptan versus placebo | 15.0Â mg Tolvaptan versus placebo | 7.5Â mg versus 15.0Â mg Tolvaptan | ||
Improvement rate of ascites (N, %) | Â | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 Day 4 | 28 (36.8) | 38 (50.0) | 10 (13.2) | 70 (45.8) | 71 (46.4) | 12 (7.8) | 152 (50.5) | 125 (41.5) | 24 (8.0) | 0.130 | 0.023 | 0.403 | |
 Day 7 | 31 (40.8) | 34 (44.7) | 11 (14.5) | 82 (53.6) | 60 (39.2) | 11 (7.2) | 180 (59.8) | 93 (30.9) | 28 (9.3) | 0.037 | 0.003 | 0.342 | |
Improvement rate of lower extremity edema (N, %) | Â | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 Day 4 | 12 (46.2) | 12 (46.2) | 2 (7.7) | 23 (51.1) | 21 (46.7) | 1 (2.2) | 48 (55.2) | 39 (44.8) | 0 (0.0) | 0.395 | 0.223 | 0.766 | |
 Day 7 | 14 (53.8) | 10 (38.5) | 2 (7.7) | 33 (71.7) | 12 (26.1) | 1 (2.2) | 60 (67.4) | 27 (30.3) | 2 (2.2) | 0.077 | 0.088 | 0.773 | |